Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$719 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.2
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.6
Face value
--
Shares outstanding
41,889,500
CFO
$-215.61 Mln
EBITDA
$-240.61 Mln
Net Profit
$-229.98 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ikena Oncology (IKNA)
| -92.7 | -91.3 | -90.2 | -92.9 | -71.4 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Ikena Oncology (IKNA)
| -16.6 | -25.9 | -78.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ikena Oncology (IKNA)
|
1.4 | 718.8 | 0.0 | -30.7 | -- | -25.4 | -- | 6.2 |
| 11.1 | 994.0 | 59.6 | -181.0 | -349.7 | -36.9 | -- | 2.1 |
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive... complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd. Read more
President, CEO & Director
Dr. Mark Manfredi Ph.D.
President, CEO & Director
Dr. Mark Manfredi Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ikena Oncology Inc (IKNA) is $1.43 (NASDAQ) as of 25-Jul-2025 16:21 EDT. Ikena Oncology Inc (IKNA) has given a return of -71.35% in the last 3 years.
Since, TTM earnings of Ikena Oncology Inc (IKNA) is negative, P/E ratio is not available.
The P/B ratio of Ikena Oncology Inc (IKNA) is 6.20 times as on 25-Jul-2025, a 57 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.61
|
0.63
|
|
2023
|
-1.38
|
0.55
|
|
2022
|
-1.40
|
0.66
|
|
2021
|
-13.18
|
2.16
|
|
2020
|
--
|
--
|
The 52-week high and low of Ikena Oncology Inc (IKNA) are Rs 23.28 and Rs 1.36 as of 04-Apr-2026.
Ikena Oncology Inc (IKNA) has a market capitalisation of $ 719 Mln as on 25-Jul-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Ikena Oncology Inc (IKNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-15.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.